“…MMN amplitude reduction in schizophrenia is well-documented (Naatanen & Kahkonen, 2009; Nagai et al, 2013a; Umbricht & Krljes, 2005), including in chronic (Brockhaus-Dumke et al, 2005; Catts et al, 1995; Jahshan et al, 2012; Javitt, Doneshka, Zylberman, Ritter, & Vaughan, 1993; Javitt, Grochowski, Shelley, & Ritter, 1998; Javitt, Shelley, Silipo, & Lieberman, 2000b; Kiang, Braff, Sprock, & Light, 2009; Light & Braff, 2005; Magno et al, 2008; Michie et al, 2000; Oades et al, 2006; Oknina et al, 2005; Rasser et al, 2011; Salisbury, Shenton, Griggs, Bonner-Jackson, & McCarley, 2002; Shelley et al, 1991; Umbricht, Bates, Lieberman, Kane, & Javitt, 2006), recent onset (Atkinson, Michie, & Schall, 2012; Jahshan et al, 2012; Javitt et al, 2000b; Kaur et al, 2011, 2012b, 2013, Perez et al, 2014; Todd et al, 2008; Umbricht et al, 2006), and some (Bodatsch et al, 2011; Brockhaus-Dumke et al, 2005; Catts et al, 1995) but not all (Devrim-Ucok, Keskin-Ergen, & Ucok, 2008; Kirino & Inoue, 1999; Korostenskaja et al, 2005) unmedicated patients. The status of MMN in first episode schizophrenia is more controversial, with some studies reporting reduced frequency-deviant MMN (Oknina et al, 2005) or duration-deviant MMN (Bodatsch et al, 2011; Hermens et al, 2010; Kaur et al, 2011; Nagai et al, 2013b; Oades et al, 2006), at least in patients lacking any college education (Umbricht et al, 2006), but other studies reporting normal duration-deviant MMN (Magno et al, 2008) or frequency-deviant MMN (Bodatsch et al, 2011; Devrim-Ucok et al, 2008; Magno et al, 2008; Nagai et al, 2013b; Salisbury et al, 2002; Valkonen-Korhonen et al, 2003).…”